Skip to content
OpenCapital
Get started

McKesson MCK Estimated Litigation Liability, Noncurrent

Estimated Litigation Liability, Noncurrent at other companies

Cencora logo
CencoraCOR
$3.86B-10.0%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
——

Other financials

Income statement

See full
Revenue$96.3B+6.0%
Gross profit$4.0B+11.1%
Operating income$2.2B+35.1%
Net income$1.7B+33.5%
EPS (diluted)$13.65+37.6%

Balance sheet

See full
Cash & equivalents$4.0B-33.3%
Total debt$2.3B-74.2%
Total equity-$2.2B-4.7%
Total assets$82.3B+9.6%

Cash flow

See full
Operating cash flow$3.4B-55.8%
CapEx$111.0M-34.3%
Free cash flow$3.3B-56.3%

Valuation

See full
Market cap$88.46B+2.1%
Enterprise value$86.77B-8.5%
P/E18.6×-8.8×
P/S0.2×0.0×

Profitability

See full
Gross margin3.6%-0.1pp
Operating margin1.5%+0.3pp
Net margin1.2%+0.3pp
FCF margin1.4%-0.1pp

Returns & leverage

See full
Return on equity36%—
Debt / equity2×—
Current ratio0.9×0.0×

Where this comes from

Reported directly by McKesson in its filing.

Tagged under the XBRL concept us-gaap:LitigationReserveNoncurrent.

The official record: McKesson’s 10-K, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about McKesson's estimated litigation liability, noncurrent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is McKesson's estimated litigation liability, noncurrent?
McKesson (MCK) reported estimated litigation liability, noncurrent of $5.09B in Q1 2026.
How has McKesson's estimated litigation liability, noncurrent changed year-over-year?
McKesson's estimated litigation liability, noncurrent decreased by 9.1% year-over-year, from $5.6B to $5.09B.
What is the long-term trend for McKesson's estimated litigation liability, noncurrent?
Over 5 years (2021 to 2026), McKesson's estimated litigation liability, noncurrent has grown at a -8.8% compound annual growth rate (CAGR), from $8.07B to $5.09B.
What does estimated litigation liability, noncurrent mean?
This represents the estimated liability for legal proceedings and settlements that are expected to be resolved beyond the next twelve months. For pharmaceutical wholesalers, this often relates to industry-wide litigation regarding product distribution. It is a critical indicator of potential long-term legal risk and financial exposure.